Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia

BACKGROUND: Tisagenlecleucel, an anti-CD19 chimeric antigen receptor T cell therapy, has demonstrated efficacy in children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) in two multicenter phase 2 trials (ClinicalTrials.gov, NCT02435849 (ELIANA) and NCT02228096...

Descripción completa

Detalles Bibliográficos
Autores principales: Levine, John E, Grupp, Stephan A, Pulsipher, Michael A, Dietz, Andrew C, Rives, Susana, Myers, G Douglas, August, Keith J, Verneris, Michael R, Buechner, Jochen, Laetsch, Theodore W, Bittencourt, Henrique, Baruchel, Andre, Boyer, Michael W, De Moerloose, Barbara, Qayed, Muna, Davies, Stella M, Phillips, Christine L, Driscoll, Timothy A, Bader, Peter, Schlis, Krysta, Wood, Patricia A, Mody, Rajen, Yi, Lan, Leung, Mimi, Eldjerou, Lamis K, June, Carl H, Maude, Shannon L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344270/
https://www.ncbi.nlm.nih.gov/pubmed/34353848
http://dx.doi.org/10.1136/jitc-2020-002287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344270/
https://www.ncbi.nlm.nih.gov/pubmed/34353848
http://dx.doi.org/10.1136/jitc-2020-002287

Ejemplares similares